Skip to main content
Erschienen in: Journal of Gastrointestinal Surgery 2/2020

04.02.2019 | Original Article

Inferior Outcomes Associated with the Coexistence of Hepatocellular Carcinoma Recurrence and Hepatic Virus Reinfection After Living Donor Liver Transplantation

verfasst von: Kun-Ming Chan, Tsung-Han Wu, Chih-Hsien Cheng, Chen-Fang Lee, Ting-Jung Wu, Hong-Shiue Chou, Wei-Chen Lee

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Chronic viral hepatitis remains a major etiology of liver cirrhosis and hepatocellular carcinoma. Liver transplantation has been considered an effective treatment for this condition. This study aims to analyze living donor liver transplantation for patients with hepatocellular carcinoma and its relationship with hepatitis virus status.

Methods

A retrospective analysis of 268 patients who received living donor liver transplantation for hepatocellular carcinoma was performed. Patients were analyzed according to their serologic status of hepatitis virus; clinicopathologic features, operative parameters, and outcomes were also assessed and compared.

Results

Twenty-three patients (8.6%) had hepatocellular carcinoma recurrence following liver transplantation; the most common pattern of recurrence was systemic spreading (n = 10). Hepatitis B virus relapse was encountered in 41 out of 188 patients (21.8%) with hepatitis B virus-positive, and hepatitis C virus reactivation was noted in 48 (60.8%) patients among 79 hepatitis C virus-positive patients. Incidence of hepatitis C virus reactivation was significantly higher than that of hepatitis B virus relapse (p < 0.0001). Hepatocellular carcinoma recurrence and overall survival were not significantly different in relation to hepatitis virus; however, patients who had hepatocellular carcinoma recurrence combined with hepatitis virus reinfection had the significantly lowest survival rate compared with other groups (p < 0.0001).

Conclusion

Living donor liver transplantation based on expanded hepatocellular carcinoma criteria achieved a satisfactory result, but reinfection of hepatic virus remains a great concern particularly in patient with hepatitis C. Moreover, hepatocellular carcinoma recurrence accompanied with reinfection of hepatic virus after liver transplantation is associated with inferior outcomes.
Literatur
1.
Zurück zum Zitat Lee SD, Lee FY, Wu JC, Hwang SJ, Wang SS, Lo KJ. The prevalence of anti-hepatitis C virus among Chinese patients with hepatocellular carcinoma. Cancer 1992;69:342–5.CrossRef Lee SD, Lee FY, Wu JC, Hwang SJ, Wang SS, Lo KJ. The prevalence of anti-hepatitis C virus among Chinese patients with hepatocellular carcinoma. Cancer 1992;69:342–5.CrossRef
2.
Zurück zum Zitat Liaw YF, Lin DY, Chen TJ, Chu CM. Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Liver 1989;9:235–41.CrossRef Liaw YF, Lin DY, Chen TJ, Chu CM. Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Liver 1989;9:235–41.CrossRef
3.
Zurück zum Zitat Sherlock S. Viruses and hepatocellular carcinoma. Gut 1994;35:828–32.CrossRef Sherlock S. Viruses and hepatocellular carcinoma. Gut 1994;35:828–32.CrossRef
4.
Zurück zum Zitat Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379:1245–55.CrossRef Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379:1245–55.CrossRef
5.
Zurück zum Zitat Dhir M, Melin AA, Douaiher J, Lin C, Zhen WK, Hussain SM, et al. A Review and Update of Treatment Options and Controversies in the Management of Hepatocellular Carcinoma. Ann Surg 2016;263:1112–25.CrossRef Dhir M, Melin AA, Douaiher J, Lin C, Zhen WK, Hussain SM, et al. A Review and Update of Treatment Options and Controversies in the Management of Hepatocellular Carcinoma. Ann Surg 2016;263:1112–25.CrossRef
6.
Zurück zum Zitat Chan KM, Chou HS, Wu TJ, Lee CF, Yu MC, Lee WC. Characterization of hepatocellular carcinoma recurrence after liver transplantation: perioperative prognostic factors, patterns, and outcome. Asian J Surg 2011;34:128–34.CrossRef Chan KM, Chou HS, Wu TJ, Lee CF, Yu MC, Lee WC. Characterization of hepatocellular carcinoma recurrence after liver transplantation: perioperative prognostic factors, patterns, and outcome. Asian J Surg 2011;34:128–34.CrossRef
7.
Zurück zum Zitat Wu TJ, Chen TC, Wang F, Chan KM, Soong RS, Chou HS, et al. Large fragment pre-S deletion and high viral load independently predict hepatitis B relapse after liver transplantation. PLoS One 2012;7:e32189.CrossRef Wu TJ, Chen TC, Wang F, Chan KM, Soong RS, Chou HS, et al. Large fragment pre-S deletion and high viral load independently predict hepatitis B relapse after liver transplantation. PLoS One 2012;7:e32189.CrossRef
8.
Zurück zum Zitat Chan KM, Wang YC, Wu TH, Lee CF, Wu TJ, Chou HS, et al. The Preference for Anterior Approach Major Hepatectomy: Experience Over 3 Decades and a Propensity Score-Matching Analysis in Right Hepatectomy for Hepatocellular Carcinoma. Medicine (Baltimore) 2015;94:e1385.CrossRef Chan KM, Wang YC, Wu TH, Lee CF, Wu TJ, Chou HS, et al. The Preference for Anterior Approach Major Hepatectomy: Experience Over 3 Decades and a Propensity Score-Matching Analysis in Right Hepatectomy for Hepatocellular Carcinoma. Medicine (Baltimore) 2015;94:e1385.CrossRef
9.
Zurück zum Zitat Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33:1394–403.CrossRef Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33:1394–403.CrossRef
10.
Zurück zum Zitat Lee WC, Wu TJ, Chou HS, Lee CF, Chan KM, Cheng SS. Flexible and individualized treatment to achieve sustained viral response for recurrent hepatitis C in liver transplant recipients. J Viral Hepat 2010;17:770–7.CrossRef Lee WC, Wu TJ, Chou HS, Lee CF, Chan KM, Cheng SS. Flexible and individualized treatment to achieve sustained viral response for recurrent hepatitis C in liver transplant recipients. J Viral Hepat 2010;17:770–7.CrossRef
11.
Zurück zum Zitat Wu TJ, Chan KM, Chou HS, Lee CF, Wu TH, Chen TC, et al. Liver transplantation in patients with hepatitis B virus-related hepatocellular carcinoma: the influence of viral characteristics on clinical outcome. Ann Surg Oncol 2013;20:3582–90.CrossRef Wu TJ, Chan KM, Chou HS, Lee CF, Wu TH, Chen TC, et al. Liver transplantation in patients with hepatitis B virus-related hepatocellular carcinoma: the influence of viral characteristics on clinical outcome. Ann Surg Oncol 2013;20:3582–90.CrossRef
12.
Zurück zum Zitat Park GC, Song GW, Moon DB, Lee SG. A review of current status of living donor liver transplantation. Hepatobiliary Surg Nutr 2016;5:107–17.PubMedPubMedCentral Park GC, Song GW, Moon DB, Lee SG. A review of current status of living donor liver transplantation. Hepatobiliary Surg Nutr 2016;5:107–17.PubMedPubMedCentral
13.
Zurück zum Zitat Pillai VG, Chen CL. Living donor liver transplantation in Taiwan-challenges beyond surgery. Hepatobiliary Surg Nutr 2016;5:145–50.PubMedPubMedCentral Pillai VG, Chen CL. Living donor liver transplantation in Taiwan-challenges beyond surgery. Hepatobiliary Surg Nutr 2016;5:145–50.PubMedPubMedCentral
14.
Zurück zum Zitat Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A, et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012;13:e11–22.CrossRef Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A, et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012;13:e11–22.CrossRef
15.
Zurück zum Zitat Fung J, Lo R, Chan SC, Chok K, Wong T, Sharr W, et al. Outcomes including liver histology after liver transplantation for chronic hepatitis B using oral antiviral therapy alone. Liver Transpl 2015;21:1504–10.CrossRef Fung J, Lo R, Chan SC, Chok K, Wong T, Sharr W, et al. Outcomes including liver histology after liver transplantation for chronic hepatitis B using oral antiviral therapy alone. Liver Transpl 2015;21:1504–10.CrossRef
16.
Zurück zum Zitat Saab S, Yeganeh M, Nguyen K, Durazo F, Han S, Yersiz H, et al. Recurrence of hepatocellular carcinoma and hepatitis B reinfection in hepatitis B surface antigen-positive patients after liver transplantation. Liver Transpl 2009;15:1525–34.CrossRef Saab S, Yeganeh M, Nguyen K, Durazo F, Han S, Yersiz H, et al. Recurrence of hepatocellular carcinoma and hepatitis B reinfection in hepatitis B surface antigen-positive patients after liver transplantation. Liver Transpl 2009;15:1525–34.CrossRef
17.
Zurück zum Zitat Chun J, Kim W, Kim BG, Lee KL, Suh KS, Yi NJ, et al. High viremia, prolonged Lamivudine therapy and recurrent hepatocellular carcinoma predict posttransplant hepatitis B recurrence. Am J Transplant 2010;10:1649–59.CrossRef Chun J, Kim W, Kim BG, Lee KL, Suh KS, Yi NJ, et al. High viremia, prolonged Lamivudine therapy and recurrent hepatocellular carcinoma predict posttransplant hepatitis B recurrence. Am J Transplant 2010;10:1649–59.CrossRef
18.
Zurück zum Zitat Gane EJ, Angus PW, Strasser S, Crawford DH, Ring J, Jeffrey GP, et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007;132:931–7.CrossRef Gane EJ, Angus PW, Strasser S, Crawford DH, Ring J, Jeffrey GP, et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007;132:931–7.CrossRef
19.
Zurück zum Zitat Lake JR. Do we really need long-term hepatitis B hyperimmune globulin? What are the alternatives? Liver Transpl 2008;14 Suppl 2:S23–6.CrossRef Lake JR. Do we really need long-term hepatitis B hyperimmune globulin? What are the alternatives? Liver Transpl 2008;14 Suppl 2:S23–6.CrossRef
20.
Zurück zum Zitat Faria LC, Gigou M, Roque-Afonso AM, Sebagh M, Roche B, Fallot G, et al. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterology 2008;134:1890–9; quiz 2155.CrossRef Faria LC, Gigou M, Roque-Afonso AM, Sebagh M, Roche B, Fallot G, et al. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterology 2008;134:1890–9; quiz 2155.CrossRef
21.
Zurück zum Zitat Lee MH, Yang HI, Yuan Y, L'Italien G, Chen CJ. Epidemiology and natural history of hepatitis C virus infection. World J Gastroenterol 2014;20:9270–80.PubMedPubMedCentral Lee MH, Yang HI, Yuan Y, L'Italien G, Chen CJ. Epidemiology and natural history of hepatitis C virus infection. World J Gastroenterol 2014;20:9270–80.PubMedPubMedCentral
22.
Zurück zum Zitat Joshi D, Pinzani M, Carey I, Agarwal K. Recurrent HCV after liver transplantation-mechanisms, assessment and therapy. Nat Rev Gastroenterol Hepatol 2014;11:710–21.CrossRef Joshi D, Pinzani M, Carey I, Agarwal K. Recurrent HCV after liver transplantation-mechanisms, assessment and therapy. Nat Rev Gastroenterol Hepatol 2014;11:710–21.CrossRef
23.
Zurück zum Zitat Schulze-Krebs A, Preimel D, Popov Y, Bartenschlager R, Lohmann V, Pinzani M, et al. Hepatitis C virus-replicating hepatocytes induce fibrogenic activation of hepatic stellate cells. Gastroenterology 2005;129:246–58.CrossRef Schulze-Krebs A, Preimel D, Popov Y, Bartenschlager R, Lohmann V, Pinzani M, et al. Hepatitis C virus-replicating hepatocytes induce fibrogenic activation of hepatic stellate cells. Gastroenterology 2005;129:246–58.CrossRef
24.
Zurück zum Zitat Belli LS, Burroughs AK, Burra P, Alberti AB, Samonakis D, Camma C, et al. Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study. Liver Transpl 2007;13:733–40.CrossRef Belli LS, Burroughs AK, Burra P, Alberti AB, Samonakis D, Camma C, et al. Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study. Liver Transpl 2007;13:733–40.CrossRef
25.
Zurück zum Zitat Bahra M, Neumann UP, Jacob D, Langrehr JM, Berg T, Neuhaus R, et al. Fibrosis progression in hepatitis C positive liver recipients after sustained virologic response to antiviral combination therapy (interferon-ribavirin therapy). Transplantation 2007;83:351–3.CrossRef Bahra M, Neumann UP, Jacob D, Langrehr JM, Berg T, Neuhaus R, et al. Fibrosis progression in hepatitis C positive liver recipients after sustained virologic response to antiviral combination therapy (interferon-ribavirin therapy). Transplantation 2007;83:351–3.CrossRef
26.
Zurück zum Zitat Picciotto FP, Tritto G, Lanza AG, Addario L, De Luca M, Di Costanzo GG, et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 2007;46:459–65.CrossRef Picciotto FP, Tritto G, Lanza AG, Addario L, De Luca M, Di Costanzo GG, et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 2007;46:459–65.CrossRef
Metadaten
Titel
Inferior Outcomes Associated with the Coexistence of Hepatocellular Carcinoma Recurrence and Hepatic Virus Reinfection After Living Donor Liver Transplantation
verfasst von
Kun-Ming Chan
Tsung-Han Wu
Chih-Hsien Cheng
Chen-Fang Lee
Ting-Jung Wu
Hong-Shiue Chou
Wei-Chen Lee
Publikationsdatum
04.02.2019
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 2/2020
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-019-04116-0

Weitere Artikel der Ausgabe 2/2020

Journal of Gastrointestinal Surgery 2/2020 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.